logo
welcome
Gizmodo

Gizmodo

Novo Nordisk’s mega-dose version of semaglutide lost more body weight than usual in a large-scale trial

Gizmodo
Summary
Nutrition label

77% Informative

Novo Nordisk's semaglutide lost substantially more body weight than usual in a large-scale trial.

The findings exceed the typical weight loss results seen with the existing drugs Ozempic and Wegovy .

The higher-dose version is expected to face stiff competition from other drug candidates.

VR Score

78

Informative language

82

Neutral language

52

Article tone

semi-formal

Language

English

Language complexity

58

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links